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INTRODUCTION 
Graves’ ophthalmopathy is a debilitating disease impairing the 
quality of life of the affected individuals. Despite recent progress in 
the understanding of its pathogenesis, treatment is often not sa ­
tisfactory. In mild cases, local therapeutic measures (artificial tears 
and ointments, sunglasses, nocturnal eyes taping, prisms) can con­
trol symptoms and signs. In severe forms of the disease, aggressive 
measures are required. The management strategy for moderate to­ 
severe Graves’ ophthalmopathy is controversial. Systemic steroids are 
often effective(1­4), but relapse is common when they are tapered or 
withdrawn(5). A number of retrospective studies have reported the 
efficacy of orbital irradiation(6,7) but prospective studies have shown 
conflicting results(8­10). Some investigators have suggested that ste ­
roids provide excellent improvement in orbital inflammation in the 
short term, whereas the effects of orbital irradiation take longer to 
appear(11). Studies that have compared combination therapy of or ­
bi tal irradiation and systemic steroids with steroids alone therapy 
have produced conflicting results(12­18). The accomplishment of a 
sys tematic review is the best manner for describing the state of our 
knowledge, and hence becomes the best way of obtaining high 
qua lity scientific evidence. Consequently, this systematic review was 
proposed to analyze the results from clinical trials that compared ra ­
diotherapy to any other treatment.
Radiation therapy for Graves’ ophthalmopathy: a systematic review and  
meta-analysis of randomized controlled trials
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ABSTRACT
Purpose: To evaluate the efficacy of radiotherapy (RT) with total dose of 20 Gy 
(RT 20 Gy) in the treatment of Graves’ ophthalmopathy. 
Methods: A systematic review and meta­analysis of randomized controlled trials 
was performed comparing RT 20 Gy with or without glucocorticoid to cli nical 
treatments for Graves’ ophthalmopathy. The MEDLINE, EMBASE, Cochrane Library 
databases and recent relevant journals were searched. Relevant reports were 
reviewed by two reviewers. Response to radiotherapy was defined as clinical 
success according to each trial. We also evaluated the quality of life and whether 
RT to produce fewer side effects than other treatments. 
Results: A total of 8 randomized controlled trials (439 patients) were identified. 
In the subgroup analysis, the overall response to treatment rates was better for: 
RT 20 Gy plus glucocorticoid vs glucocorticoids alone, OR=17.5 (CI95% 1.85­250, 
p=0.04), RT 20 Gy vs sham RT, OR= 3.15 (CI95%1.59­6.23, p=0.003) and RT 20Gy plus 
intravenous glucocorticoid vs RT 20Gy plus oral glucocorticoid, OR=4.15(CI95% 
1.34­12.87, p=0.01). There were no differences between RT 20 Gy versus other 
fractionations and RT 20 Gy versus glucocorticoid alone. RT 20 Gy with or without 
glucocorticoids showed an improvement in diplopia grade, visual acuity, optic 
neuropathy, lid width, proptosis and ocular motility. No difference was seen for 
costs, intraocular pressure and quality of life. 
Conclusion: Our data have shown that RT 20 Gy should be offered as a valid the ­
rapeutic option to patients with moderate to severe ophthalmopathy. The effecti­
veness of orbital radiotherapy can be increased by the synergistic interaction with 
glucocorticoids. Moreover, RT 20 Gy is useful to improve a lot of ocular symptoms, 
excluding intraocular pressure, without any difference in quality of life and costs.
Keywords: Graves ophthalmopathy; Exophthalmos; Radiotherapy; Meta­analysis, 
Review
RESUMO
Objetivo: Avaliar a eficácia da radioterapia (RT ) com dose total de 20 Gy (RT 20 Gy) 
no tratamento da oftalmopatia de Graves. 
Métodos: Uma revisão sistemática e meta-análise de ensaios clínicos randomizados 
foram realizadas comparando RT 20 Gy, com ou sem glicocorticoides a tratamentos 
clinicos para a oftalmopatia de Graves. O MEDLINE, EMBASE, bases de dados da 
Biblioteca Cochrane e recentes de revistas relevantes foram pesquisados. Relatórios 
relevantes foram revisados por dois revisores. A resposta à radioterapia foi definida 
através do sucesso clinico de acordo a cada ensaio clínico. Nós também avaliamos a 
qualidade de vida e se a radioterapia produzia menos efeitos colaterais comparados 
a outras intervenções. 
Resultados: Um total de 8 ensaios clínicos randomizados (439 pacientes) foram iden -
tificados. Na análise de subgrupo, a resposta global para as taxas de tratamento foi 
melhor para: RT 20 Gy além de glicocorticoides vs glicocorticoides sozinhos, OR=17,5 
(IC95% 1,85-250, p=0,04), RT 20 Gy vs sham RT, OR=3,15 (IC95% 1,59-6,23, p=0,003) e 
RT 20 Gy além de glicocorticoides por via intravenosa RT 20 Gy além de glicocorticoides 
orais, OR=4,15 (IC95% 1,34-12,87, p=0,01). Não houve diferenças entre RT 20 Gy contra 
outros fracionamentos e 20 Gy RT contra glicocorticoides sozinhos. RT 20 Gy, com 
ou sem glicocorticoides mostraram uma melhoria no grau de diplopia, acuidade 
visual, neuropatia óptica, abertura palpebral, proptose e da motilidade ocular. Não 
foi observada diferença para os custos, a pressão intraocular e a qualidade de vida. 
Conclusão: Nossos dados mostraram que 20 Gy RT deve ser oferecida como uma opção 
terapêutica válida para pacientes com moderada a severa oftalmopatia de Graves. A 
eficácia da radioterapia orbital pode ser aumentada pela interação sinérgica com os 
glicocorticoides. Além disso, RT 20 Gy é útil para melhorar vários sintomas oculares, 
excluindo a pressão intraocular, sem qualquer diferença de qualidade de vida.
Descritores: Oftalmopatia de Graves; Exoftalmia; Radioterapia; Meta-análise, Revisão
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METHODS 
Types of sTudies 
This systematic review properly included randomized control­
led clinical trials. Any trial including only patients with mild Graves 
ophthalmopathy (GO), or any trial including patients with modera­
te­severe GO were included. The participants of studies included 
patients with GO diagnosis for the first time, not resistant to previous 
treatment and with no age limit. The intervention criteria to be in­
cluded in this review was any trial in which radiotherapy with total 
dose of 20 Gy associated or not to glucocorticoid (of any kind) was 
the primary treatment compared to radiotherapy (RT) with total 
dose different of 20 Gy, no radiotherapy or any another treatment. 
The efficacy of radiotherapy was evaluated following measures 
after treatment. The lid width was measured as the widest vertical 
dimension, proptosis was measured by an exophthalmometer, ocular 
motion was measured in degrees or constancy of diplopia, intraocu­
lar pressure measured using an applanation tonometer, optic nerve 
function was assessed by recording of the corrected visual acuity 
or fundoscopy. Response to radiotherapy was defined as clinical 
suc cess according to each trial. We also evaluated the quality of life 
and whether RT produced fewer side effects than other treatments. 
Medline and manual searches were done (completed independently 
and in duplicate) to identify all published (manuscripts and abstracts) 
randomized controlled trials (RCTs) that compared radiotherapy for 
GO to any treatment. The Medline search was done between 1966 
and 2006 with no language restrictions, using the search terms 
“ophthalmopathy,” orbitopathy” and “Graves’ ophthalmopathy,” “ra­
diotherapy” or “orbital radiotherapy,” and “retro ocular radiotherapy”. 
The second search was done through EMBASE and the Cochrane Li ­
brary to identify randomized trials published between January 1998 
and July 2006, using MeSH headings (ophthalmopathy, orbipathy, 
Graves’ ophthalmopathy, orbital radiotherapy, retro ocular radiothe­
rapy /sc {Secondary}, ex­lode Clinical Trials, clinical trial {publication 
type}) and text words (retro ocular radiotherapy radiotherapy, Graves’ 
ophthalmopathy, trial, and study) without language restrictions. All 
the searched abstracts were screened for relevance. Manual searches 
were done by reviewing articles and abstracts cited in the reference 
lists of identified RCTs, by reviewing the first author’s article, abstract 
file, from reference lists of retrieved papers, textbooks and review 
articles. Hand searches were carried out in the following journals 
between January Ophthalmology; Lancet; Ophthalmology; Internatio-
nal Journal of Radiation Oncology, Biology, and Physics; and Journal of 
Clinical endocrinology and metabolism. Reference lists from identified 
studies and other relevant publications were scrutinized. Colleagues, 
collaborators, and other experts were contacted about ongoing and 
unpublished trials. From the titles and abstracts, relevant RCTs were 
identified. Two independent reviewers (V.A.G., A.C.B.) then assessed 
the RCTs to establish if predetermined inclusion criteria were met. 
Study suitableness was assessed using QUOROM criteria(19). The RCTs 
were also independently assessed for quality according to predeter­
mined criteria (method of randomization, blinding, statistical me­
thods, quality of life assessment, data completeness, follow­up), and 
the data extracted and tabulated. Discrepancies between the two 
reviewers were resolved by discussion. The intention was to carry out 
a meta­analysis of outcomes if there were enough trials of sufficient 
quality and homogeneity.
sTaTisTics 
The efficacy of radiotherapy treatment with total dose of 20 Gy 
was measured through the response to treatment described in each 
trial. Responders to treatment were defined as patients who presen­
ted overall response to radiotherapy or other treatment, according 
to clinical success defined according to each trial. The data analyses 
were made with Review Manager Version 5.1 provided by The Coch­
rane Collaboration. All analyses were carried out on an intention 
to treat basis; that is, all patients randomly assigned to a treatment 
group were included in the analyses according to the assigned treat­
ment, irrespective of whether they received the treatment or were 
excluded from analysis by the investigators. For categorical variables, 
weighted risk ratios and their 95% confidence interval were calcu­
lated using RevMan 5.1 software according to the Peto method(20). 
Results were tested for heterogeneity at significance level of P<0.05 
according to the methods outlined by Der Simonian and Laird(21). A 
fixed effects model was used if there was no evidence of heterogenei­
ty between studies, if there was evidence of heterogeneity random 
effects model was used for meta­analysis.
The odds ratio and 95% confidence interval were calculated for 
each trial and presented in a Forrest plot. Sensitivity analyses was 
performed by excluding the trials which Jadad­scale was only 1 score. 
Publication bias is a common concern in meta­analysis that is rela­
ted to the tendency of journals to favor the publication of large and 
positive studies. We chose a commonly used method for detecting 
publication bias, which is a graphical plot of estimates of the ORs from 
the individual studies versus the inverse of their variances, which is 
commonly referred to as a “funnel plot.” An asymmetry in the funnel 
would be expected if there was publication bias with smaller studies 
tending to show larger ORs, because small studies with no significant 
statistical results would be less likely to be reported. 
RESULTS 
sTudy characTerisTics 
A total of 359 studies of treatment of GO were identified, from 
which we excluded those that did not involve the use of RT, thus 
limiting the selection to 22 studies. Of these only 8 were controlled 
clinical studies. Fourteen studies were excluded due to lack of origi­
nal data, insufficient data for analysis, lack of randomization and/or 
retrospective design, no control group, earlier reports on individual 
studies. A total of 8 studies were included in this review(8­10,12­16), as 
demonstrated in the figure 1. Study characteristics are shown in ta ­
ble 1. The studies were clearly heterogeneous, so we divided them 
into six groups: 
 A. 1 randomized studies (15 patients) that assessed the efficacy 
and safety of combined orbital irradiation and systemic steroids 
in the management of moderate­to­severe Graves’ ophthal­
mopathy(16). 
 B. 3 studies (190 patients) tested the efficacy of external beam 
irradiation compared with sham­irradiation(9,10,15). 
 C. 1 study (82 patients) assessed the efficacy and safety of orbital 
radiotherapy combined with either oral glucocorticoid or iv 
glucocorticoids(14). 
 D. 1 study (66 patients) compared the efficacy and tolerability of 
three RT protocols(12). 
 E. 1 study (56 patients) evaluated the efficacy of combined the­
rapy RT plus systemic methylprednisolone or systemic methyl­
prednisolone alone. 
 F. 1 study (30 patients) compared the efficacy of combined the­
rapy RT plus systemic glucocorticoids plus and radiotherapy 
alone(13). 
The studies had a randomized design with 209 patients submitted 
to RT with or without glucocorticoids and 230 patients submitted 
to other treatment(9,10,12­16). The parameters evaluated in these stu­
dies were: Quality of life, costs, proptosis, visual acuity, diplopia, 
intraocular pressure, optic neuropathy, ocular motility and clinical 
response. Seven studies included in this review tested the efficacy 
of RT 20 Gy to improve proptosis(9,10,12,14­16). However, only in the stu­
dy performed by Marcocci et al.,(14) there was significant difference 
between the two modalities of treatment. Five studies investigated 
the lid width(9,10,12,14,15) again Marcocci et al.,(14) was the only study to 
demonstrate significant difference. The visual acuity was evaluated in 
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RT: radiation therapy; RCT: randomized controlled trial.
Figure 1. Flowchart according to QUOROM statement criteria.
three RCTs,(12,13,16) only one trial(13) showed benefit for RT 20 Gy arms. 
Diplopia was assessed in five RCTs(9,10,12,14,15) of these studies Prummel 
et al.,(15) and Mourits et al.(9) founded significant differences between 
radiotherapy versus sham radiotherapy for changes in diplopia, in 
the other studies it was not seen. Intraocular pressure was tested in 
two RCTs(12,16), one performed by Ng et al.(16), and another by Kahaly 
et al.(12), in both studies no benefit was seen in combined orbital 
irradiation and systemic steroids or using low dose of radiotherapy. 
Mar cocci et al.(14), was the only trial to assess the efficacy of radiothe­
rapy to improve optic neuropathy. In this study combined orbital 
irradiation and systemic steroids were associated with significant 
difference to improve optic neuropathy. 
Ocular motility and clinical response was tested in all RCTs(8­10,12­16). 
RT 20 Gy with or without glucocorticoid achieved significant statisti­
cal difference in five of the eight trials evaluated for clinical response. 
Ocular motility was improved in six trials(8,9,13­16) comparing RT 20 Gy 
with other treatments. Table 2 summarizes the parameters evalua­
ted and the treatment results. According to the Jadad criteria, we 
assessed the quality of the randomized and comparative trials with 
regard to: a) method of randomization, b) treatment allocation, c) 
similarity between groups, d) specification of eligible criteria, e) blin­
ded outcome of assessor, care provider and patient(22). Applying these 
criteria made clear that the quality of the trials was high, as showed 
in the table 3 which describes in details the trials design, aim, study 
question, results, and conclusions. 
response To TreaTmenT 
All the studies reported response to treatment as one of the out ­
comes. The criterions for evaluation of the response to treatment 
were heterogeneous between the trials. Altogether, the analyses 
included 8 trials with 439 patients(9, 10, 12­16). The individual odds ratios 
ranged from 0.87 to 17.5 with a pooled odds ratio for all of the trials 
of 2.14 with a 95% confidence interval of 1.44 to 3.18. The test for 
heterogeneity was not statistically significant with p value 0.14, which 
indicates that the pooling of the data was valid. The overall odds ratio 
suggests that there is difference between RT 20 Gy arms and other 
treatments in terms of response to treatment rate with p value 0.0002, 
as shown in the figure 2. 
radioTherapy versus sham radioTherapy 
Three trials(9,10,15) with 190 patients evaluated response to treat­
ment comparing radiotherapy versus sham radiotherapy. The in ­
dividual odds ratios ranged from 1 to 3.5 with a pooled odds ratio 
for all of the trials of 3.15 with a 95% confidence interval of 1.59 to 
6.23. The test for heterogeneity was not statistically significant with 
p value 0.28, which indicates that the pooling of the data was valid. 
Viani GA, et al.
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Table 1. Characteristics of the patients, parameters of the treatment, status of GO and end points of the studies included in this meta-analysis
Trial (year)
Patients/ 
treatment Diagnostic
Status GO/treatment 
hypertireoidism
Equipament 
Dose/angle/field End point 
Prummel et al., 
(2004)
88
RT: 44
NO RT: 44 
Signs and symptoms with  
enlarged extraocular eye muscles on 
coronal computed tomography scan 
of the orbits
Mild, antithyroid drugs, 
TSH supression 
Linear accelerator/
20Gy/3 grade anterior/ 
5 X 5 cm
After 12 months, motility in 
degrees,
proptosis, lid aperture, 
diplopia, quality life, cost 
Marcocci et al., 
(2001)
82
RT+IVGC:41
RT+ORGC:41
Signs and symptoms with enlarged 
extraocular eye muscles on coronal 
computed tomography scan of the 
orbits
Moderate­to­severe 
methimazole
for 3­4 months before 
radioiodine therapy
Linear accelerator/20Gy10
degrees anterior/
4 X 4 cm 
After 12 months, motility in 
degrees,
proptosis, lid aperture, optic 
neuropathy, diplopia 
Kahaly et al.,  
(2000)
62
A=18 1 Gray/week
20 Gray/20 weeks
B=22 1 Gray/day
10 Gray/2 weeks
C=22 2 Gray/day
20 Gray/2 weeks 
Signs and symptoms with enlarged 
extraocular eye muscles on magnetic 
resonance imaging (MRI)
Mild to moderate eye 
disease, euthyroidism, 
antithyroid drugs 
Linear accelerator/20Gy­10 
Gy/3 degrees anterior/ 
5 X 6 cm
After 12 months, lid aperture, 
proptosis, motility in degrees, 
diplopia, intraocular pressure
Ng et al., (2005) 16
RT+GC:8
GC:8
Signs and symptoms with enlarged 
extraocular eye muscles on 
computed tomography or  
magnetic resonance imaging (MRI)
Moderate­to­severe 
ophthalmopathy, 
anti­thyroid drugs, 
radioactive iodine, 
thyroidectomy 
Linear accelerator/20Gy­10 
Gy/10 degrees anterior/ 
4 X 4 cm
After 12 months, motility  
in degrees,
proptosis, lid aperture
Bartalena et al., 
(1983)
48
RT+GC36
GC:12
Signs and symptoms with enlarged 
extraocular eye muscles 
Moderate­to­severe 
ophthalmopathy, 
anti­thyroid drugs, 
radioactive iodine, 
thyroidectomy
Cobalt ­60/20Gy­10 Gy/10 
degrees anterior/
4 X 4 cm
After 12 months,  
ophthalmic index,
proptosis, optic neuropathy
Gorman et al., 
(2002)
42
RT:21
NO RT:21
Signs and symptoms with enlarged 
extraocular eye muscles on 
computed tomography
Mild to moderate 
ophthalmopathy
anti­thyroid drugs, 
radioactive iodine, 
thyroidectomy
Linear accelerator/20Gy­10 
Gy/10 degrees anterior/
4 X 4 cm
After 6 months, motility 
in degrees,
proptosis, lid aperture,  
clinical activity scores 
Prummel et al., 
(1993)
56
RT:28
GC:28
Signs and symptoms with enlarged 
extraocular eye muscles
Moderate 
ophthalmopathy
anti­thyroid drugs, 
radioactive iodine, 
thyroidectomy
Linear accelerator or cobalt 
­60/20Gy­10 Gy/10 degrees 
anterior/
5 X 5 cm
After 6 months,
eye score and a decrease in 
eye­muscle volume
Mourits et al.,  
(2000)
60
RT: 30
NO RT: 30
Signs and symptoms with enlarged 
extraocular eye muscles on coronal 
computed tomography scan of the 
orbits
Moderate­to­severe 
ophthalmopathy, 
anti­thyroid drugs, 
radioactive iodine, 
thyroidectomy
Linear accelerator/20Gy­10 
Gy/10 degrees anterior/
4 X 4 cm
After 6 months,
eyelid aperture, proptosis, 
eye movements, subjective 
eye score, and clinical­activity
RT: radiation therapy; NO RT: no radiation therapy; GC: glucocorticoid; IV: intravenous; TSH: thyroid­stimulating hormone.
Table 2. Ocular parameters and results post treatment evaluated in randomized clinical trails
Trial 
Prummel 
1993
Marcocci*
2000
Bartalena
1983
Ng
2005
Kahaly
2000
Mourits
2001
Prummel
2004
Gorman
2001
Parameter 
Quality of life 0 0 0 0 0 0 = 0
Proptosis (mm) = + 0 0 0 0 0 0
Lid width (mm) 0 + 0 0 0 0 0 0
Visual acuity 0 0 0 = = 0 0 0
Diplopia 0 = 0 0 = + + =
Intraocular pressure = = = 0 0 0 0 0
Optic neuropathy 0 + + 0 0 0 0 0
Ocular motility + + + + = + + =
Clinical response = + + + = + + =
Cost 0 0 0 0 0 0 = 0
Side effects ­ ­ + = ­ + + +
*= Marcocci trial + was used for RT 20 Gy plus IV glucocorticoid and 0 was used for RT 20 Gy plus oral glucocorticoid; += significant for radiotherapy 20 Gy arms with or without gluco­
corticoids when compared to the other treatment; ­= significant for another treatment; (=)= no difference between the arms of study; 0= no evaluation.
Radiation therapy for Graves’ ophthalmopathy: a systematic review and meta-analysis of randomized controlled trials
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Table 3. Description of the design, aim, question, results and conclusion of the studies included in this meta-analysis
Author Year 
Design /aim/ 
study question Results Conclusions/comments 
Prummel et al.,  
2004
Double­blind
randomized trial
To compared RT efficacy with sham 
irradiation in mild ophthalmopathy
RT was successful in 23 of 44 (52%) irradiated patients vs. 12 of 
44 (27%) sham­irradiated patients at 12 months after treatment 
(relative risk, 1.9; 95% CI, 1.1 ­ 3.4; P =0.02). was effective in 
improving eye muscle motility and decreasing the severity of 
diplopia. Quality of life improved similarly in both groups. In the 
radiotherapy group there was less need for follow­up treatment; 
66% vs. 84% of the patients needed further treatment (P=0.049)
RT is an effective treatment in mild 
ophthalmopathy. The improvement upon 
irradiation may not be associated with an 
increase in quality of life or a reduction in 
treatment costs
Ng et al.,  
2005
Double­blind
randomized trial
To assess the efficacy and safety 
of combined orbital irradiation 
and systemic steroids in the 
management of moderate­to­
severe Graves’ ophthalmopathy
Total eye score improved earlier in the SRT group, achieving 
statistical significance (P<0.05) at as early as 4 weeks of follow­up. 
Improvement in ocular parameters was greater and led to a 
significantly greater reduction in total eye score than in the 
steroids group at weeks 16, 24, and 52. Maximum extra­ocular 
muscle thickness was significantly reduced in the steroids plus 
RT group only. No change was observed in proptosis in either 
group. No serious adverse effect was observed with the addition 
of orbital irradiation to steroid therapy
A combination of orbital RT and systemic 
steroids is well tolerated and more effective 
than steroids alone in the treatment of active 
moderate­to­severe Graves’ ophthalmopathy. 
It achieves greater and more rapid 
improvement in soft tissue swelling, ocular 
motility, and visual acuity
Prummel et al.,  
1993 
Double­blind
randomized trial
A successful outcome was observed in 14 prednisone­treated 
and in 13 RT patients. Responders to treatment (but not 
nonresponders) in both groups showed improvements in total 
and subjective eye score and a decrease in eye­muscle volume. 
Response to either treatment was due largely to changes in soft­
tissue involvement and eye­muscle motility. Mean elevation in 
responders to radiotherapy increased from 18.5 degrees  
(95% CI 14.8 ­ 22.2) at baseline to 21.8 degrees (18.6 ­ 25.0) at 
week twenty­four (p=0.003), but did not change in prednisone 
responders. Side­effects were more frequent and severe during 
prednisone than during radiotherapy.
RT and oral prednisone appear to be equally 
effective as initial treatment in patients with 
moderately severe Graves’ ophthalmopathy. 
In view of its better tolerability, radiotherapy 
should be considered the treatment of first 
choice
Marcocci et al.,  
2001
Randomized trial
To assess the efficacy and safety of 
orbital radiotherapy combined with 
either oral (prednisone; starting 
dose, 100 mg/d; withdrawal after 5 
months) or IV (methylprednisolone; 
15 mg/kg for four cycles and then 
7.5mg/kg for four cycles; each 
cycle consisted of two infusions 
on alternate days at 2­wk intervals) 
glucocorticoids
A significant reduction in proptosis (from 23.2 ± 3.0 to  
21.6 ± 1.2 mm in the IV glucocorticoid group, P<0.0001; and 
from 23 ± 1.8 to 21.7 ± 1.8 mm in oral glucocorticoid group,  
P <0.0001) and in lid width (from 13.3 ± 2.5 to 11.8 ± 2.2 mm, and 
from 13.6 ± 2.0 to 11.5 ± 1.9 mm, respectively; P<0.001 in both 
cases) occurred, with no difference between the two groups. 
Diplopia significantly improved in both groups: it disappeared in 
13 of 27 (48.1%) IV glucocorticoid patients (P<0.005) and in 12 of  
33 (36.4%) oral glucocorticoid patients (P<0.03)
High­dose IV glucocorticoid and 
oral glucocorticoid (associated with 
orbital radiotherapy) are effective in 
the management of severe Graves’ 
ophthalmopathy, but the IV route seems to 
be more effective and better tolerated than 
the oral route and associated with a lower 
rate of side effects
Gorman et al.,  
2001
Prospective, randomized, internally 
controlled, double­blind clinical trial
To evaluate the efficacy of 
radiotherapy for GO
No clinically or statistically significant difference between the 
treated and untreated orbit was observed in any of the main 
outcome measures at 6 months. At 12 months, muscle volume 
and proptosis improved slightly more in the orbit that was 
treated first
This study was unable to demonstrate 
any beneficial therapeutic effect. The 
slight improvement noted in both orbits 
at 12 months may be the result of natural 
remission or of radiotherapy, but the 
changes are of marginal clinical significance
Kahaly et al.,  
2000
Randomized trial
 
To compare the efficacy and 
tolerability of three Rx protocols.
Response to therapy, defined as a significant amelioration 
of three objective parameters, was noted in 12 A (67%), 13 B 
(59%), and 12 C (55%) subjects (C vs. A, P 5 0.007). Ophthalmic 
symptoms and signs regressed most in group A; changes in lid 
fissure width were 21.5, 20.5, and 0 mm in the A, B, and C groups, 
respectively (A vs. C, P<0.005), whereas changes in intraocular 
pressure (upgaze) were 23, 11, and 21.5 mmHg, respectively  
(A vs. B, P 5 0.002)
Patients with moderately severe GO, similar 
response rates were observed for low and 
high Rx doses, but the 1 Gy/week protocol 
was more effective and better tolerated than 
the short arm regimens
Bartalena et al.,  
1983
Randomized trial
To asses the efficacy to either 
combined therapy or systemic 
methylprednisolone alone
Patients treated by combined therapy, 12 (33%) showed 
excellent responses, 14 (39%) showed good responses, 9 (25%) 
showed slight responses, and 1 (3%) had no response. Treatment 
was more effective for soft tissue involvement, newly developed 
ophthalmoplegia, and optic neuropathy, while proptosis and 
longstanding ophthalmoplegia were less responsive
The study indicates that both orbital RT 
combined with systemic methylprednisolone 
treatment and systemic methylprednisolone 
therapy alone are valuable methods of 
treatment for Graves’ ophthalmopathy, but 
the combined therapy proved to be more 
effective
Mourits et al.,  
2000
Double­blind
randomized trial
Tested the efficacy of external  
beam irradiation compared with 
sham­irradiation
The qualitative treatment outcome was successful in  
18 of 30 (60%) irradiated patients versus nine of 29 (31%) 
sham­irradiated patients at week 24. This difference was caused 
by improvements in diplopia grade, but not by reduction of 
proptosis, nor of eyelid swelling
In these patients with moderately severe 
Graves’ ophthalmopathy, radiotherapy 
should be used only to treat motility 
impairment
RT: radiation therapy; GO: Graves’ ophthalmopathy.
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The overall odds ratio suggests that there is difference between RT 
20 Gy arms and no RT 20 Gy arms in terms of response to treatment 
rate with p value 0.003, as shown in table 4.
radioTherapy plus glucocorTicoid versus glucocorTicoid
One randomized study(16) (15 patients) compared the efficacy of 
combined orbital irradiation and systemic steroids in the manage­
ment of moderate­to­severe Graves’ ophthalmopathy. The odds ratio 
for this trial was of 17.50 with a 95% confidence interval of 1.85 to 
250. The test for heterogeneity was not statistically significant with p 
value 0.42, which indicates that the pooling of the data was valid. The 
overall odds ratio suggests that there is difference between RT 20 Gy 
arms and glucocorticoid arms in terms of response to treatment rate 
with p value 0.04, as demonstrated in the table 4. 
radioTherapy plus iv glucocorTicoid versus radioTherapy plus 
oral glucocorTicoid 
One study(14) (82 patients) compared the efficacy radiotherapy 
plus IV glucocorticoid versus radiotherapy plus oral glucocorticoid.
The odds ratio of this study was 4.15 with 95% confidence inter­
val of 1.34 to 12.87, suggesting that there is difference between 
radiotherapy plus IV glucocorticoid versus radiotherapy plus oral 
glucocorticoid in terms of response to treatment with p value 0.01, 
shown in table 4. 
radioTherapy wiTh 20 gy versus oTher fracTionaTions 
One study (12) (66 patients) compared the efficacy of radiotherapy 
with a total dose of 20 Gy versus others fractionations. The odds ratio 
of this study was 1.10 with 95% confidence interval of 0.39 to 3.10, 
suggesting that there is no difference between radiotherapy with a 
total dose of 20 Gy versus others fractionations for response to treat­
ment, as demonstrated in table 4. 
QualiTy of life and cosTs
One study of Prummel et al.,(15)(88 patients) evaluated the quality 
of life and costs and did not evidence differences in quality of life 
or costs between patients submitted to radiotherapy versus sham 
radiotherapy for GO.
radioTherapy versus glucocorTicoid 
One study(8) (56 patients) compared the efficacy of radiotherapy 
with a total dose of 20 Gy versus glucocorticoid. The odds ratio of 
this study was 0.87 with 95% confidence interval of 0.30 to 2.87, 
suggesting that there is no difference between radiotherapy with a 
total dose of 20 Gy versus glucocorticoid for response to treatment, 
as described in table 4.
radioTherapy plus iv glucocorTicoid versus radioTherapy alone 
One study(13) (30 patients) compared the efficacy of radiotherapy 
plus IV glucocorticoid versus radiotherapy alone. The odds ratio this 
study was 3 with 95% confidence interval of 0.68 to 13.31, suggesting 
that there is no difference between radiotherapy with a total dose of 
20 Gy plus glucocorticoid versus radiotherapy alone for response to 
treatment, as shown in table 4. 
QualiTy of sTudies 
The median of the quality scores was of 4 points (in a 5­point 
scale), with none study scoring 0, 1, 2, or 3. There was complete agre­
ement in scoring by the two assessors. The quality scores were high, 
five trials scored 5 points (8­10,15,16) and three trials scored 4 points in the 
Jada scale. This fact occurred because of the importance placed on 
blinding in the scoring system, and the inherent difficulty in blinding 
a treatment such as radiation, as shown in the table 3. 
evaluaTion of publicaTion bias 
The funnel plot of the log ORs versus the inverse of their variances 
of the individual studies is displayed in figure 3. The plot formed a very 
distinct funnel shape with the log ORs evenly distributed around the 
meta­analysis OR regardless the study variance. Therefore, there was 
no indication of an asymmetry in the study findings by the variance 
or size of the studies and, thus, little evidence for publication bias. 
DISCUSSION 
External radiotherapy has been used for GO for around 60 years 
and it still represents a mainstay in the management of the disease(23). 
The rationale for the use of radiotherapy for GO resides both in its 
OR: odds ratio.
Figure 2. Treatment response comparing radiation therapy 20 Gy to other treatments in the randomized controlled trial.
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Table 4. Odds ratio calculated according to the response to treat-
ment for the trials included in this meta-analysis
Estimated OR (95% CI), p value
Response to treatment (n=439)
RT 20 Gy vs sham RT (n=190)
Prummel et al., 2004(15)
Mourits et al., 2000(9)
Gorman et al., 2001(10)
3.15 (1.59 ­ 6.23), p=0.003
2.92 (1.2 ­ 7.1)
3.50 (1.2 ­ 10.2)
1.00 (0.26 ­ 3.87)
RT 20 Gy plus glucocorticoid vs  
glucocorticoid (n=15)
Ng et al., 2005(16)
17.5 (1.22 ­ 250), p=0.04
RT 20 Gy IVGC vs RT ORGC * (n=82)
Marcocci et al., 2001(14)
4.15 (1.34 ­ 12.87), p=0.01
RT 20 Gy vs glucocorticoid (n=56)
Prummel et al., 1993(8)
0.87 (0.30 ­ 2.47), p=0.79
RT 20 Gy vs Low dose RT (n=66)
Kahaly et al., 2000(12)
1.10 (0.39 ­ 3.10), p=0.86
RT 20 Gy plus glucocorticoid vs  
RT 20 Gy (n=30) 
Marcocci et al., 1991(13) 
3.00 (0.68 ­ 13.31), p=0.15
OR= odds ratio; CI= confidence interval; NR= not reported; RT= radiotherapy.
*= IV methylprednisoloneacetate (IVGC) or oral prednisone (ORGC).
nonspecific anti­inflammatory effect and in the high radio sensitivity 
of lymphocytes infiltrating the orbital space(24). Lymphocytes are ge­
nerally suppressed with relatively low doses of radiation, and the hel­
per/suppressor T lymphocyte ratio is also altered by radiotherapy(23). 
In addition, radiotherapy might also reduce glycosaminoglycans 
production by orbital fibroblasts(25). Whether the reported effective­
ness of orbital radiotherapy in GO is related either to its nonspecific 
anti­inflammatory action, or to specific immunosuppressive effects, 
both need to be clarified. Our review of papers published between 
1983 and 2006 showed that positive results were obtained using RT. 
According to most studies, orbital radiotherapy is especially effective 
on soft tissue inflammatory changes and recent extraocular muscle 
involvement, producing improvement in the ocular parameters as 
visual acuity, diplopia, proptosis, lid width, ocular motility and op­
tic neuropathy, but without any benefit on intraocular pressure. It 
should be mentioned that all studies were randomized, controlled 
and of high quality. The latest 5 years have witnessed important dis­
cussions on the role of orbital radiotherapy, in particular questioning 
its effectiveness and safety(26­32). 
Most authors agree that orbital radiotherapy is a safe procedure. 
If the technique of radiation is correct, it seems not to increase the 
risk of cataract and retinopathy, except for patients with diabetic and 
hypertensive retinopathy(33,34). The two latter conditions, especially 
if associated, should be considered as relative contraindications 
to orbital radiotherapy, in particular when signs of retinopathy are 
present before irradiation. It is worth noting that, even after a very 
long follow­up, orbital radiotherapy does not seem to bear a risk of 
radiation­induced tumors(35­40). Thus, the safety of orbital radiotherapy 
is not a major matter of argument, but there is a controversy about 
its real effectiveness. This debate has been revitalized by a randomi­
zed, placebo­controlled, double­blind study from the Mayo Clinic(10). 
In the original experimental design of this study, only one orbit of 
42 patients with moderately severe GO was irradiated, whereas the 
contralateral orbit served as an internal control. A detailed analysis of 
objective measures was provided; leading the authors to conclude 
that orbital radiotherapy is ineffective and therefore, should not be 
offered to GO patients(10). Although Gorman et al. should be congra­
tulated on the major effort they made, our point about this study is 
that it has some structural errors. 
One of them was the fact that a lot of patients had a long­
stan ding ophthalmopathy and had been already treated before, 
apparently not well succeeded, by systemic glucocorticoids(10). The 
second one involves timing of therapy, and the therapeutic goals 
of orbital radiation therapy. The authors in their study included 
pa tients between 0.2 and 16 years, with a median of 1.3 years with 
onset from the eye symptoms. The authors made no attempt to 
treat patients in the active progressive phase of thyroid eye disease. 
This phase disease is characterized by infiltration of the extra­ocular 
muscles with lymphocytes, and it is the prime radiation sensitive 
period. Patients who do not respond to glucocorticoids are unli­
kely to show any benefit from orbital radiotherapy. In addition, the 
obser vation that the untreated orbit did not show any improve­
ment or worsening during the 6­months period of further observa­
tion suggesting that enrolled patients had stable, non progressive, 
i.e. inactive (“burnt­out”) eye disease. The third vital error was the 
stated goal of orbital radiation. In many institutions the stated goal 
of therapy is to halt or reverse severe progressive thyroid ophthal­
mopathy. The author’s therapeutic objectives of treating patients 
who had chronic fibrotic thyroid ophthalmopathy established 
were unclear. This article seemed to evaluate if radiation therapy 
reversed such findings as orbital volume in patients with chronic 
thyroid ophthalmopathy. Our final concern about this article was 
the unusual port design for radiation therapy. This design may be 
useful as a research data, on the other hand, being human studies 
it can be considered as worrisome. Treating with their wedge pair 
field design to spare the contralateral eye, the authors increased the 
volume of normal tissue significantly, including the frontal lobes 
and parotid glands, exposed to radiation compared to the standard 
opposed lateral fields. Although the risks of a secondary malignancy 
in the treatment of those patients are slight, increasing the volume 
would be expected to increase this risk. But the long­term effects 
of a low dose radiation in a larger volume of the frontal lobe may 
have subtle effects in the higher brain functions. 
What did the other randomized controlled trials tell us about 
the efficacy of orbital radiotherapy for GO? In 1993, a randomized 
double­blind trial of prednisone vs. orbital radiotherapy in patients 
with moderately severe GO(8) demonstrated that the proportion of 
responders in prednisone­treated (14 of 28, 50%) and irradiated (13 of 
28, 46%) patients (18%) was similar. That time, there were no doubts 
that glucocorticoid was an effective treatment for GO. Ho wever, from 
this study through non direct comparison RT has star ted to be also 
considered effective. In addition, the study above also demonstrated 
a decrease in the eye muscle volume, as assessed by the eye muscle 
score(8). In 2000 those data were confirmed for a double­blind ran­
SE: size effect; OR: odds ratio.
Figure 3. Funnel plot for response to treatment using radiotherapy for Graves’ ophthal-
mopathy.
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domized study which included 60 patients with moderately severe 
GO who were submitted to either orbital radiotherapy or sham­irra­
diation(9). The qualitative treatment outcome was successful in 60% 
of irradiated patients and in only 31% of sham irradiated patients(9). 
Improvement was mainly confined to eye movements; it should also 
be noted that 25% of irradiated patients were saved from additional 
strabismus surgery(9). In 2004 a new important information(15) about 
the use of orbital radiotherapy was provided for GO by Prummel et 
al. This double­blind, randomized clinical trial was the first to address 
the question of whether orbital radiotherapy has a place in the ma­
nagement of nonsevere GO. Based on the evaluation of changes in 
major and minor criteria prespecified, primary therapeutic outcome 
was successful in 52% of irradiated patients and in only 27% of 
sham­ir radiated patients(15), with improvement in the eye muscle 
function and diplopia. It should also be noted that the orbital radio­
therapy was not associated with a greater improvement of quality of 
life, compared to sham irradiation(15). This paper also provides valua­
ble information that orbital radiotherapy did not prevent progression 
to more severe expressions in about 15% of the patients. The reason 
why the severe forms of GO develop is still un clear nowadays, but it 
seems that environmental factors play a decisive role in this progres­
sion(40). Thus, if the study by Prummel et al.(15), lends further support 
to the concept that orbital radiotherapy is in general an effective 
treatment for GO, it also suggests that the commonly adopted policy 
of “wait­and­see” in cases of mild GO should be maintained, including 
the cost/benefit considerations. At present, most centers utilize linear 
accelerators delivering 4­6 megavolts and use a 4 x 4­cm lateral field 
slightly angled posteriorly to avoid as much as possible irradiation 
to the contralateral lens. The use of higher energy sources has not 
proven to be particularly advantageous. The most common delive­
red dose is 20 grays (Gy) per eye(30); this cumulative dose is usually 
fractionated in 10 daily doses over a 2­week period to reduce the 
cataractogenic effect of irradiation(27). The importance of dose was 
evaluated by Kahaly et al., (12), using different radiation doses. It repor­
ted that a therapeutic scheme of 1 Gy per week over a 20­week period 
was equally effective and possibly better tolerated than the classi cal 
2­week scheme. The use of higher cumulative doses of radiation 
(30 Gy vs. 20 Gy) does not produce any increase in the effectiveness 
of treatment(41). Irrespective of small differences observed using 
low­dose vs. high­dose radiotherapy, beneficial effects of radiothe­
rapy were observed in all the three groups of patients in 55 to 67% of 
cases. In summary, what is the message to the reader, based on the 
present systematic review? 
CONCLUSION 
Our data has shown that orbital radiotherapy still has an impor ­
tant role in the management of GO. Although there are a lot of 
avai lable studies in the literature, they have a limited impact owing 
to selection bias and lack of an appropriate ophthalmological assess­
ment. In the era of evidence­based medicine it cannot be denied 
that six of eight randomized and controlled studies showed that or­
bital radiotherapy is effective on GO, especially on extraocular mus­
cle involvement. Orbital radiotherapy, in burning out eye disease, 
can also make eye muscle and/or eyelid corrective surgery possible 
in earlier stages. The effectiveness of orbital radiotherapy can be in­
creased by the synergistic interaction with glucocorticoids. Orbital 
radiotherapy should still be offered as a valid therapeutic option to 
patients with moderate to severe GO. The selection of patients is 
fundamental, be cause patients with inactive (“burnt­out”) GO are 
unlikely to respond to irradiation (as well as to glucocorticoids). 
The use of orbital radiotherapy in the early stage of the disease 
(possibly less than 1 year from the onset) is recommended. The real 
efficacy of orbital radiotherapy should come from well­designed, 
multicenter, randomized and controlled studies enrolling a large 
number of patients. 
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